company background image
301201 logo

ChengDa Pharmaceuticals SZSE:301201 Stock Report

Last Price

CN¥21.26

Market Cap

CN¥3.2b

7D

-7.2%

1Y

-24.6%

Updated

22 Nov, 2024

Data

Company Financials

ChengDa Pharmaceuticals Co., Ltd.

SZSE:301201 Stock Report

Market Cap: CN¥3.2b

301201 Stock Overview

Engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. More details

301201 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends2/6

ChengDa Pharmaceuticals Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ChengDa Pharmaceuticals
Historical stock prices
Current Share PriceCN¥21.26
52 Week HighCN¥28.50
52 Week LowCN¥14.60
Beta0.30
11 Month Change-0.56%
3 Month Change21.21%
1 Year Change-24.61%
33 Year Changen/a
5 Year Changen/a
Change since IPO-73.54%

Recent News & Updates

ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With Earnings

Oct 08
ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With Earnings

There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price Jump

Oct 08
There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price Jump

Recent updates

ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With Earnings

Oct 08
ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With Earnings

There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price Jump

Oct 08
There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price Jump

ChengDa Pharmaceuticals (SZSE:301201) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Sep 03
ChengDa Pharmaceuticals (SZSE:301201) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last Year

Jul 05
ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last Year

Shareholder Returns

301201CN PharmaceuticalsCN Market
7D-7.2%-1.5%-2.1%
1Y-24.6%-9.4%2.8%

Return vs Industry: 301201 underperformed the CN Pharmaceuticals industry which returned -4.8% over the past year.

Return vs Market: 301201 underperformed the CN Market which returned 5.4% over the past year.

Price Volatility

Is 301201's price volatile compared to industry and market?
301201 volatility
301201 Average Weekly Movement9.2%
Pharmaceuticals Industry Average Movement7.3%
Market Average Movement8.3%
10% most volatile stocks in CN Market12.6%
10% least volatile stocks in CN Market5.6%

Stable Share Price: 301201 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 301201's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980557Gang Luwww.chengdapharm.com

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers APIs; bulk drugs for urogenital, musculoskeletal system, and antineoplastic and immunomodulators; and drug intermediates for blood and hematopoietic organs, digestive tract and metabolism, and nervous system. The company was founded in 1980 and is based in Jiaxing, China.

ChengDa Pharmaceuticals Co., Ltd. Fundamentals Summary

How do ChengDa Pharmaceuticals's earnings and revenue compare to its market cap?
301201 fundamental statistics
Market capCN¥3.22b
Earnings (TTM)CN¥70.19m
Revenue (TTM)CN¥397.81m

45.9x

P/E Ratio

8.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301201 income statement (TTM)
RevenueCN¥397.81m
Cost of RevenueCN¥223.85m
Gross ProfitCN¥173.96m
Other ExpensesCN¥103.77m
EarningsCN¥70.19m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.46
Gross Margin43.73%
Net Profit Margin17.64%
Debt/Equity Ratio0%

How did 301201 perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

44%

Payout Ratio